Opzelura® (Ruxolitinib)-Creme ist der erste steroidfreie topische JAK-Hemmer, der in der Europäischen Union für Erwachsene mit mittelschwerer atopischer Dermatitis zugelassen wurde
Wednesday, July 29, 2026 1 min read
Key Takeaway: Incyte announced that the European Commission has approved Opzelura® (Ruxolitinib) cream for treating moderate atopic dermatitis in adults. This approval is significant as it offers a new, steroid-free treatment option for patients who have not responded adequately to topical corticosteroids and calcineurin inhibitors. The approval is seen as a major milestone for both Incyte and patients in Europe.
Market Sentiment Analysis
POSITIVE FACTORS
First steroid-free topical JAK inhibitor approved in the EU.
Provides a new treatment option for adults with moderate atopic dermatitis.
Approval marks a significant milestone for Incyte and patients.
Full Press Release Details
WILMINGTON, Delaware--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) gab heute bekannt, dass die Europäische Kommission (EK) die Opzelura® (Ruxolitinib)-Creme zur Behandlung mittelschwerer atopischer Dermatitis (AD) bei erwachsenen Patienten zugelassen hat, bei denen topische Kortikosteroide (TCS) und topische Calcineurin-Hemmer (TCI) unzureichend oder ungeeignet sind. „Die Zulassung von Opzelura durch die Europäische Kommission ist ein wichtiger Meilenstein für Erwachsene in Europa, die an mittelschwer
Frequently Asked Questions
What is Opzelura®?
Opzelura® is a steroid-free topical JAK inhibitor cream used to treat moderate atopic dermatitis.
Who is Opzelura® approved for?
It is approved for adults with moderate atopic dermatitis who have not responded well to other treatments.
What does the EU approval signify?
The approval signifies a significant milestone in providing new treatment options for patients in Europe.
What are the alternatives to Opzelura®?
Alternatives include topical corticosteroids and topical calcineurin inhibitors, which may be inadequate or unsuitable.